Curing America’s Most Expensive Health Crisis

Today, more than 5 million Americans suffer from Alzheimer’s disease, and millions more will be diagnosed in the years to come.

But those days could soon be over.

I’ve discovered a small group of biotech companies with drugs in development that have the potential to do much more than just mask Alzheimer symptoms. In fact, they’re being designed to attack the disease at its roots, possibly halting its progression.

That’s great news for anyone affected by Alzheimer’s and also opens up a huge profit opportunity for you — a chance to make life-changing wealth.

Here’s what you need to know…

A Next-Level Alzheimer’s Breakthrough

As I mentioned earlier, a small group of biotechs is racing to create what could be one of most important drugs in biotech history.

To understand how it works, you first need to know a bit about how the disease progresses. According to the most accepted theory, it all comes down to proteins.

Proteins are intricate molecules that play a diverse role in all living things. They are made up of sequences of smaller molecules. There are billions of possible ways to arrange these sequences.

If a protein folds into the wrong shape for any reason, it not only might not work properly, it might become toxic.

Researchers believe that is what’s happening in the brains of Alzheimer’s patients. Their brains are filled with a misshaped “toxic” protein known as beta amyloid.

Over time, the accumulation of large amounts of toxic protein starts killing brain cells.

To fight Alzheimer’s disease, we need a way to remove these toxic beta amyloids from the body.

The tricky part is that these proteins misfold in many different variants, and each has to be identified and studied to find out what it does and why.

It’s one of the reasons progress finding a cure has been so slow. But that’s on the verge of changing, thanks to new research.

Maybe Not First… but Possibly the Best

So far, medical science has only been able to slow the disease’s progression by improving communication between affected neurons.

This is a short-term solution at best.

The need for a permanent solution is driving much of the new Alzheimer’s research.

And a small number of advanced biotech companies are on the cusp of finding a long-lasting cure.

One company’s new treatment is now in Phase 3 FDA testing, the last stage of clinical trials before the company can file a New Drug Application (NDA) asking for permission to sell.

The drug works by attaching antibodies to the beta-amyloid proteins. That signals the immune system to attack them.

While the early data from the drug have been promising, they’ve also come with an important caveat — the drug isn’t very selective.

In addition to clearing out the toxic beta amyloids, it’s clearing out the harmless plaque around them. That leaves gaps in the brain that fill with fluid, leading to a dangerous condition known as edema.

As a result drug dosage has to be strictly monitored, and doctors need to find a balance between killing the bad prions without destroying too much plaque to make this treatment more useful.

Obviously, there’s room for improvement.

That’s where another company is taking the lead — creating a treatment that specifically targets the problem proteins without damaging other brain matter.

The drug is lagging behind other companies pushing into this space, but if successful, it won’t matter.

Because bringing the best-in-class drug to market is more important than being first-in-class. And targeting those companies is what what will help you rack up profits if you move in this space.

And by moving in this space early, you’ll have the opportunity to be a part of making a great thing happen — as well as see the potential for huge profits.

For Tomorrow’s Trends Today,

Ray Blanco
for The Daily Reckoning

You May Also Be Interested In:

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, Ray Blanco’s FDA Trader, Penny Pot Profits, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco